Initiator Pharma selects Syngene and Research Toxicology Centre (RTC) as primary partners for the preclinical development of IPED2015
PRESS RELEASEApril 19th 2017 In order to accelerate Initiator Pharma’s erectile dysfunction (ED) development program, Initiator Pharma has selected Syngene, India and Research Toxicology Centre, Italy (RTC) as contract research organizations (CROs) to conduct the pre-clinical development of the drug candidate IPED2015 for the treatment of ED. The goal is to file a clinical trial application and to start a clinical Phase I trial in the early autumn of 2018 as planned. Both CROs are internationally highly recognized and serve pharmaceutical companies of all sizes worldwide (for more